Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00960752 · ClinicalTrials.gov registry record · Phase 2
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00960752: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00960752 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00960752, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
Interventions
- DRUG gp100
- DRUG R848 gel
- DRUG MAGE-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-05-20 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00960752
The ClinicalTrials.gov registry entry for NCT00960752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gp100 is the first listed.
NCT00960752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00960752 about?
NCT00960752 is a clinical study titled "Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist". The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
What is the current status of trial NCT00960752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2010-05-20. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT00960752?
The interventions under investigation include: gp100 (DRUG), R848 gel (DRUG), MAGE-3 (DRUG).
Who is sponsoring clinical trial NCT00960752?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.